Table 1.
Study populations.
| ICPCGa | PLCOb | NFPCSc | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Case | Control | Case | Control | Case | ||||
| Affected in pedigree | nr | ≥ 3 | 2 | nr | nr | 0 | ≥ 3 | 2 | 1 |
| European ancestry, count | 1383 | 2505 | 2 | 2841 | 4599 | 823 | 331 | 344 | 31 |
| Aggressive | 56% | 50% | nr | 22% | 43% | 48% | |||
| Mean age at Dx or screen | nr | 60 | 54 | 68 | 69 | 63 | 60 | 56 | 46 |
| < 60 years | nr | 45% | 50% | 8% | 6% | 43% | 48% | 67% | 97% |
| ≥ 60 years | nr | 55% | 50% | 92% | 94% | 57% | 52% | 33% | 3% |
Dx, diagnosis; nr, not recorded.
aSubjects of 12 aggregated studies of the International Consortium for Prostate Cancer Genetics (ICPCG, dbGaP phs000733.v1.p1).
bSubjects of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial's Prostate Cancer Genome-Wide Association Study for Uncommon Susceptibility Loci (PEGASUS, dbGaP phs000882.v1.p1).
cSubjects of the Nashville Familial Prostate Cancer Study (NFPCS). All subjects are genetically independent and of European ancestry. Aggressive is defined: ≥ pT3, or N1, or M1, or Gleason ≥ 8, or PSA ≥ 20 ng/ml, or lethal prostate cancer.